Author(s) Details:
Khaled Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Roberto De Giorgio
Department of Translational Sciences, University of Ferrara, Ferrara, Italy.
Rami Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
This section is a part of the chapter: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review
The limited efficacy of most treatment options represents a significant concern among IBS-C patients, which further intensifies the overall impact of this condition. A retrospective cohort study that included a sample of 2,830 patients with IBS-C found that 46.3% exhibited at least one indication of treatment failure within a one-year follow-up period (Guerin et al. 2014). The cohort consisted of 1,627 patients who initially utilized over-the-counter (OTC) medications, 1,107 who received prescription medications, and 96 who employed a combination of both treatment types. The study identified several indicators of treatment failure, including the need to switch or increase IBS-C or constipation therapies, hospital admissions related to IBS-C or constipation complications, occurrences of megacolon or fecal impaction, surgical interventions associated with constipation, and the initiation of more intense prescription treatments (Guerin et al. 2014). Traditional laxative treatments for managing IBS-C symptoms often lack effectiveness (Jadallah et al. 2014, Shin et al. 2024). Considering the significant challenges associated with IBS-C and the pressing demand for safe and effective therapeutic alternatives, it is important to note that the options currently available for clinical use remain relatively limited. It is mandatory to develop pharmacological therapies that address all aspects of IBS-C comprehensively, particularly abdominal pain, constipation, and related symptoms, to enhance the overall quality of life for patients.
How to Cite
Jadallah, K., Giorgio, R. D., & Jadallah, R. (2025). Pharmacological Advancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review. Medical Science: Trends and Innovations Vol. 4, 49–85. https://doi.org/10.9734/bpi/msti/v4/4177